Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

Simponi and Simponi Aria (golimumab) are prescribed to treat a variety of inflammatory conditions. Kroger is cutting about 200 employees across three office sites, and Albertsons is laying off ...

The FDA accepted the biologics license applications (BLA) for AVT05, Alvotech’s and Teva Pharmaceuticals’ proposed biosimilar to golimumab (Simponi and Simponi Aria), which treats inflammatory ...

Alvotech’s proposed biosimilar to Simponi and Simponi Aria (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced ...

About BAT2506 (golimumab) BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule.

The FDA is set to review the Biologics License Applications (BLAs) for Alvotech’s AVT05, a proposed biosimilar to Simponi and Simponi Aria, branded forms of golimumab, which is a medication prescribed ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...